Spark Plug Pipe

According to a report published by Coherent Market Insights, the global medical cannabis market was valued at USD 3.5 Billion in 2017 and is projected to grow at a compound annual growth rate (CAGR) of 24.4% to surpass USD 20.17 Billion by 2025. The report indicated that the increasing clinical trials and approvals of medical cannabis products will drive the growth of the market. Medical cannabis is used to develop drugs that will enhance the treatment for diseases such as epilepsy and various types of cancers. Additionally, the growing acceptance of the mobile application, e-commerce and digital media is projected to fuel the growth of the medical cannabis market during forecast years. MariCann Group Inc. (OTC:MRRCF), MariMed Inc. (OTC:MRMD), TerrAscend Corp. (OTC:TRSSF), Leafbuyer Technologies, Inc. (OTC:LBUY), Emblem Corp. (OTC:EMMBF)

On June 19th, Canada had legalized cannabis on a national level and became the first G20 country to do so. A research by PwC specifies that more than 100 licensed producers (LPs) are already in use in Canada’s cannabis industry, with hundreds more awaiting government approval. Most LPs are in startup mode, despite being operational for a few years. Darren Henderson, Partner at PwC Canada’s Technology, InfoComm, and Entertainment & Media consulting explained, “The cannabis industry is blossoming. With the upcoming legalization of cannabis for recreational use by the Federal Government, the sector is expected to grow as producers, manufacturers, and companies from across the value chain embrace opportunities in both the recreational and medical markets.”

MariCann Group Inc. (OTCQB:MRRCF) is also listed on the Canadian Securities Exchange under the ticker (CNSX:WAYL.CN). Yesterday, the Company announced, “receipt of accreditation for its proprietary education program for pharmacists from the Canadian Council on Continuing Education in Pharmacy (the CCCEP).

The Company has identified that pharmacists are the most accessible and one of the most trusted health professionals in the Canadian healthcare system which makes them a critical component in the provision of patient care. In cooperation with the Company’s joint venture pharmacy partners, Wayland developed cannabis education programs, including this comprehensive online education platform to raise the standard of care across Canada. These programs will be available to pharmacists in over 2,100 pharmacies, coast to coast.

Wayland believes that there is a national need for education and more importantly practical guidance for medical cannabis therapy, assessment, dosing and monitoring to ensure safe and appropriate use for patients. As many cannabis patients present with comorbidities and take multiple medications, which require appropriate management to help avoid adverse side effects.

The Wayland program incorporates online learning tools including, webinars, educational events and educational resources specifically for pharmacists and clinicians. The Educational Program, which launched on October 1, 2018 – is accredited by the CCCEP for pharmacists on the clinical and practical application of cannabinoid therapy. In addition, it includes practice guides, instructional videos, dosing protocols and patient support materials which can be used by physicians and the full circle of care.

‘We’re proud to elevate the standard of care provided to patients through an expert led educational platform that provides pharmacists and physicians the ability to become experts in cannabis and share this with their patients to enhance their quality of life,’ said Ben Ward, CEO. ‘We’re taking this platform now to other countries to help medical professionals understand cannabis, so they can speak in plain language to their patients regarding potential benefits.’

Maricann Group Inc., through its subsidiaries, is operating under the Wayland Group name. For further details see the press release dated September 24, 2018.”

MariMed Inc. (OTCQB:MRMD) is a multi-state professional cannabis organization that develops, owns and manages cannabis facilities and branded products lines. MariMed, Inc. recently announced that it had consummated its strategic investment in Sprout, an all-in-one CRM and marketing software company for marijuana dispensaries and cannabis brands. This completes the previously announced MariMed LOI for investment in Cannabis Venture Partners, parent company of Sprout. “The cannabis industry needs a comprehensive software solution which integrates a full featured CRM engine and platform for marketing, education, and analysis for brands, dispensaries, educators, and researchers,” said MariMed Chief Executive Officer Robert Fireman. “The Sprout platform has the foundation for these functions and more. MariMed will work with the Sprout team to make this software the best for the cannabis industry. This product enables MariMed to provide a bundled technology solution for its brands, facilities, and strategic partnerships incorporating both B2B and B2C communications.”


TerrAscend Corp. (OTC:TRSSF) is a biopharmaceutical and wellness company that is committed to quality products, brands and services for the global cannabinoid market. TerrAscend Corp. recently announced that the Company has entered into an agreement with the MDM Insurance Services Inc. to establish a program for medical cannabis coverage and a framework for research on cannabis and medication utilization. “TerrAscend and Solace Health Network represent opportunity and choice for patients that may benefit from cannabinoid therapy. Working with MDM on a program to provide patient education, assessment, reimbursement and additional services, will facilitate the appropriate integration of medical cannabis as an option to aid patients,” shared Dr. Michael Nashat, TerrAscend’s President & Chief Executive Officer. “Additionally, we are looking forward to establishing a credible body of evidence to guide innovation and the future of medical cannabis.”


Leafbuyer Technologies, Inc. (OTCQB:LBUY) is one of the most comprehensive online sources for cannabis deals and information. Leafbuyer works alongside cannabis businesses to showcase their unique products and build a network of loyal patrons. The Company recently announced that yearly sales rose 42% in the fiscal year ending June 30th, 2018. The increase reflects the cash sales booked in the year versus the previous year. The Company reported that sales in new markets have been steadily increasing as marketing efforts have taken hold and sales staff have been put in place. “Our overall strategy of broadening our platform to become a true comprehensive marketing solution has allowed us to attract many new customers and upsell current ones. The average monthly spend for new customers has increased more than 50% in the last six months as we continue to offer a wider basket of solutions. We have also been investing heavily in development (online ordering, loyalty and block chain) and are starting to see the results in sales numbers. We are very excited about what is happening right now in the industry. Canada will be legalizing this month; the U.S. elections are a month away and we are rolling out great product enhancements across our network. Building and broadening the platform while scaling in new markets across the country is our ongoing focus,” said Mark Breen, Chief Operating Officer and Vice President of Sales of Leafbuyer.

Emblem Corp. (OTCQX:EMMBF), through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Emblem Corp., along with Canntab Therapeutics Limited, recently announced that they have achieved a milestone with regards to the development of a patent-pending oral extended release formulation for cannabinoids. “Emblem’s strength in the medical market is further solidified by achievement of this major milestone. We believe the oral extended release formulation will be a game-changer in the medical cannabis market and that Emblem, through its license agreement with Canntab, is at the forefront of this development,” said Nick Dean, Chief Executive Officer. “Precise, dose-controlled cannabis medications are critical to the acceptance of cannabis among prescribers and patients. Emblem has long been a medical-first LP and our first and foremost commitment is to our patients. Innovative cannabis products for both the medical and adult-use space are fundamental to our long-term strategy, alongside brand building and distribution.”

Subscribe Now! Watch us report LIVE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned within this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Maricann Group Inc. financial news dissemination, has been compensated four thousand dollars by winning media. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:

For further information:Media